Back
Return
Biography
网搜

Dr. Masakazu Toi
Kyoto University, Japan


Email: toi@kuhp.kyoto-u.ac.jp


Qualifications

2007 Professor, Kyoto University, Japan

2003-Present Professor, Science University of Tokyo, Japan

2003 Guest Professor, Hong Kong University, Japan


Publications (Selected)

  1. Procter M, Suter TM, de Azambuja E, Dafni U, Van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WTW, Toi M, Coombes CR, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC,
  2. Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ. Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol 2010 28:3422-8.
  3. Kondo M, Hoshi SL, Yamanaka T, Ishiguro H, Toi M. conomic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat. 2010 Nov 17. [Epub ahead of print]
  4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010 2010:162-77. (As one of 610 collaborators)
  5. Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, Toi M, Funata N, Eishi Y. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med Dent Sci. 2010 57:155-63.
  6. Horiguchi K, Toi M, Horiguchi S, Sugimoto M, Naito Y, Hayashi Y, Ueno T, Ohno S, Funata N, Kuroi K, Tomita M, Eishi Y. Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci. 2010 57:165-75.
  7. Kitagawa D, Saji S, Horiguchi S, Satoh Y, Horiguchi K, Toi M, Funata N, Kuroi K. Alternation of estrogen receptor and progesterone receptor expression in primary breast cancer patients treated with neoadjuvant chemotherapy. Breast J. 2010 16:435-6. Epub
  8. Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 2010 116:3112-8.
  9. Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemother Pharmacol. 2010 Jul 14
  10. Chen L, Endler A, Uchida K, Horiguchi S, Morizane Y, Iijima O, Toi M, Shibasaki F. Int6/eIF3e silencing promotes functional blood vessel outgrowth and enhances wound healing by upregulating hypoxia-induced factor 2alpha expression. Circulation. 2010 122:910-9.
  11. Toi M, Ohashi Y, Seow A, Moriya T, Tse G, Sasano H, Park BW, Chow LW, Laudico AV, Yip CH, Ueno E, Ishiguro H, Bando H. The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer. Jpn J Clin Oncol. 2010 Sep;40 Suppl 1:i13-18.
  12. Yiu CC, Chanplakorn N, Chan MS, Loo WT, Chow LW, Toi M, Sasano H. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. Anticancer Res. 2010 30:3465-72.
  13. Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan. Clin Ther. 32:311-326, 2010.
  14. Toi M, Sperinde J, Huang W, Saji S, Winslow J, Jin X, Tan Y, Ohno S, Nakamura S, Iwata H, Masuda N, Aogi K, Morita S, Petropoulos C, Bates M. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer. BMC Cancer 2010 Feb 23;10:56. [Epub ahead of print]
  15. Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat. 2010 Feb 12. [Epub ahead of print]
  16. Kimura Y, Tsuji W, Yamashiro H, Toi M, Inamoto T, Tabata Y. In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor. J Tissue Eng Regen Med. 4:55-61, 2010.
  17. Shimbo T, Fukui T, Ishioka C, Okamoto K, Okamoto T, Kameoka S, Sato A, Toi M, Matsui K, Mayumi T, Saji S, Miyazaki M, Takatsuka Y, Hirata K. Quality of guideline development assessed by the Evaluation Committee of the Japan Society of Clinical Oncology. Int J Clin Oncol. 2010 15:227-33. Mar 24. [Epub ahead of print]
  18. Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 2010 Mar 31. [Epub ahead of print]
  19. Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 101:1676-82, 2009.
  20. Kondo M, Hoshi SL, Toi M. Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan. Br J Cancer. 27: 281-290, 2009.